apg101
Recombinant proteinexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01071837)
Timeline
Indications
Mechanism of action
- Tumor necrosis factor ligand superfamily member 6BINDING AGENT
Tumor necrosis factor ligand superfamily member 6 binding agent
FAS inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297886 ↗
Also known as
- apg101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05639192 | Phase 3 | Nov 3, 2022 | Apogenix GmbH |
| NCT04535674 | Phase 2 | Oct 9, 2020 | Apogenix GmbH |
| NCT03158389 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | Deutsche Krebshilfe e.V., German Cancer Research Center, University of Heidelberg |
| NCT01736436 | Phase 1 | Jan 1, 2013 | Apogenix GmbH |
| NCT01071837 | Phase 2 | Dec 1, 2009 | Apogenix GmbH, University of Heidelberg |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apogenix GmbH | For profit | 4 | 4 | 3 | 2009 |
| University of Heidelberg | Academic/Hospital | 2 | 1 | 1 | 2009 |
| Deutsche Krebshilfe e.V. | Academic/Hospital | 1 | 0 | 1 | 2017 |
| German Cancer Research Center | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1